ArticleEuropean radiology2023
Distinguishing common renal cell carcinomas from benign renal tumors based on machine learning: comparing various CT imaging phases, slices, tumor sizes, and ROI segmentation strategies.
Article in European radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Artificial intelligence in the radiologic diagnosis of major urological cancers: a meta-analysis.World journal of urology · 2026Pooled it
- Diagnostic performance of artificial intelligence in detection of renal cell carcinoma: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Artificial Intelligence computed tomography models for the discrimination of Wilms versus non-Wilms tumors: systematic review and meta-analysis.Jornal brasileiro de nefrologiaPooled it
- Optimizing Deep Learning for Renal Mass Characterization in Challenging Cases: A Comparative Study of Spatial-Input Strategies and a Validated ROI-Only DLR Nomogram.Annals of surgical oncology · 2026Article
- ASO Author Reflections: From Four Spatial-Input Strategies to a Full Exhaustive Paradigm-Refining Deep Learning Radiomics for Challenging Renal Masses.Annals of surgical oncology · 2026Article
- Prospective evaluation ofAnnals of nuclear medicine · 2026Article
- CT-Based Radiomics in the Characterization of Solid Renal Tumors: A Systematic Review.Cancers · 2026Review
- NerveAI- a machine learning algorithm for detection of nerve pain in the head and neck.Scientific reports · 2026Article
- Multimodal deep learning model for multiclass classification of renal tumors.NPJ digital medicine · 2026Article
- Machine learning based classification of aggressive and malignant renal tumors from multimodal data.PLOS digital health · 2026Article
- CT-based AI score associates with perioperative outcomes in nephron-sparing surgery for renal cell carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- CT-based conventional radiomics and quantification of intratumoral heterogeneity for predicting benign and malignant renal lesions.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Review
- Radiomics analysis based on single phase and different phase combinations of radiomics features from tri-phasic CT to distinguish renal oncocytoma from chromophobe renal cell carcinoma.Abdominal radiology (New York) · 2024Article
- Diffuse large B-cell lymphoma of renal origin with hemophagocytic syndrome: a lesson for the clinical nephrologist.Journal of nephrology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
objectivesTo determine whether a CT-based machine learning (ML) can differentiate benign renal tumors from renal cell carcinomas (RCCs) and improve radiologists' diagnostic performance, and evaluate the impact of variable CT imaging phases, slices, tumor sizes, and region of interest (ROI) segmentation strategies.
methodsPatients with pathologically proven RCCs and benign renal tumors from our institution between 2008 and 2020 were included as the training dataset for ML model development and internal validation (including 418 RCCs and 78 benign tumors), and patients from two independent institutions and a public database (TCIA) were included as the external dataset for individual testing (including 262 RCCs and 47 benign tumors). Features were extracted from three-phase CT images. CatBoost was used for feature selection and ML model establishment. The area under the receiver operating characteristic curve (AUC) was used to assess the performance of the ML model.
resultsThe ML model based on 3D images performed better than that based on 2D images, with the highest AUC of 0.81 and accuracy (ACC) of 0.86. All three radiologists achieved better performance by referring to the classifier's decision, with accuracies increasing from 0.82 to 0.87, 0.82 to 0.88, and 0.76 to 0.87. The ML model achieved higher negative predictive values (NPV, 0.82-0.99), and the radiologists achieved higher positive predictive values (PPV, 0.91-0.95).
conclusionsA ML classifier based on whole-tumor three-phase CT images can be a useful and promising tool for differentiating RCCs from benign renal tumors. The ML model also perfectly complements radiologist interpretations. KEY POINTS: • A machine learning classifier based on CT images could be a reliable way to differentiate RCCs from benign renal tumors. • The machine learning model perfectly complemented the radiologists' interpretations. • Subtle variances in ROI delineation had little effect on the performance of the ML classifier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.